BioCentury
ARTICLE | Financial News

Black Diamond raises $85M series C, shoots to enter clinic next half

December 5, 2019 9:55 PM UTC
Updated on Dec 6, 2019 at 4:14 AM UTC

As Black Diamond prepares to bring its first cancer candidate to the clinic and build out its tumor-agnostic pipeline, the company has raised $85 million in a oversubscribed series C led by new investor Boxer Capital.

With the raise, Black Diamond Therapeutics Inc. plans to start a Phase I/II trial evaluating lead asset BDTX-189 to treat an undisclosed cancer in 1H20. The candidate inhibits oncogenic driver mutations of the ErbB kinase family in EGFR and HER2. ...